With a July 15th $30 million series A round led by Sherpa Partners, PAQ joins a growing number of biotechs developing autophagy-dependent degraders that could push targeted degradation beyond protein substrates. ...
Launched by a co-founding team that includes a pair of Novo Nordisk veterans, Hemab is advancing a bispecific antibody the pharma had de-prioritized with the goal of addressing rare bleeding disorders beyond hemophilia. Hemab ApS...
With an asset already in the clinic for metabolic disorders, two-year-old Rivus is putting $35 million from a syndicate led by Longitude and Medicxi toward development of small molecules that act in the mitochondrial intermembrane...
CRISPR-Cas9 gene editing has only started to scratch the surface of its clinical potential, but next-generation iterations including prime editing from new company Prime aren’t far behind. Prime Medicine...
With the appointment of longtime Merck veteran Joseph Romanelli as CEO and the close of its $40 million series B, Ji Xing is poised to advance and expand its China-focused cardiovascular pipeline. Romanelli joins Ji...
Duke spinout Xilis emerged from stealth Thursday with a $70 million series A round led by Mubadala Capital to advance a miniature organoid platform designed to guide treatment decisions and accelerate drug development in cancer. ...
Sutent inventor and serial entrepreneur Chris Liang believes Hangzhou Highlightll’s TYK2/JAK1 inhibitor could deliver dual selectivity without the toxicity of a more advanced Pfizer compound against...
Former CStone and Merck & Co. dealmaker Bing Yuan and his OnCusp co-founders are using their early stage drug hunting skills to identify cancer assets from the U.S. and China that will appeal...
Putting a twist on the cross-border companies that have brought drugs from the West to the Greater China market, newly launched ArriVent is going in the other direction: sourcing innovative products from China and developing...
CellPoint is looking to broaden the accessibility and affordability of CAR T therapies with a point-of-care manufacturing platform that enables a one-week turnaround between apheresis and treatment delivery. ...
Launching with a Third Rock Ventures-led $95 million series A round, Abata joins a growing group of companies developing targeted regulatory T cell therapies for autoimmune disorders, starting with progressive multiple sclerosis. First-generation Treg cell therapies failed...
Lenz is well-financed to begin a pivotal study of a pupil-contracting eye drop addressing the largest market in ophthalmology: presbyopia, or age-related farsightedness. Backed by Versant Ventures and RA Capital, newly rechristened Lenz Therapeutics Inc. will...
Mnemo has raised the largest ever series A round for a French biotech to develop a next-generation CAR T platform and bring its cell therapies into a new target space against epigenetic antigens. Founding investor...
Forbion-backed VectorY is assembling a set of tools and key personnel to create vectorized antibody therapeutics designed to fill a gap in diseases where other mAbs and gene therapies have fallen short, beginning with ALS. Rather...
Scenic Biotech is building a compendium of genetic data to identify rare, naturally occurring genetic modifiers that suppress disease pathology despite the presence of disease-causing mutations. Many rare...
